Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04518475
Recruitment Status : Recruiting
First Posted : August 19, 2020
Last Update Posted : August 19, 2020
Sponsor:
Collaborators:
The Second Affiliated Hospital of Kunming Medical University
Henan Cancer Hospital
Tianjin Medical University Second Hospital
The First Affiliated Hospital of Xiamen University
Nantong University
Information provided by (Responsible Party):
Zhang Lei, Institute of Hematology & Blood Diseases Hospital

Brief Summary:
This multicenter randomized, open-label study aimed to compare the efficacy and safety of eltrombopag combining rituximab with eltrombopag in China adult ITP patients .This study was be conducted in adult ITP patients who had not responded to or had relapsed after previous treatment of ITP, including first line therapy and /or splenectomy.

Condition or disease Intervention/treatment Phase
Primary Immune Thrombocytopenia (ITP) Drug: eltrombopag combining rituximab Drug: eltrombopag Phase 4

Detailed Description:

The primary objective of this study was to evaluate the efficacy and safety of eltrombopag combining rituximab treating previously treated ITP patients compared to eltrombopag. The secondary objective was to evaluate the efficacy of eltrombopag combining rituximab in ITP patients with positive autoantibody compared to eltrombopag .In addition, health-related quality of life (HRQoL) measure was assessed in all participants.

224 eligible subjects were randomized to either eltrombopag combining rituximab or eltrombopag treatment in 1:1 ratio. 112 enrolled patients are randomly picked up to take eltrombopag combining with rituximab at the indicated dose. 112 enrolled patients are randomly picked up to take eltrombopag at the indicated dose.

The initial dose of eltrombopag administration was an oral 75 mg once daily in all participants .The dose of eltrombopag was adjusted according to the subject platelet count during the period from week 1 to week 24.

Subjects in eltrombopag combining rituximab treatment group received single dose infusion of rituximab 375 mg/m(2) within 14 days after enrollment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 224 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Open-label Study To Compare The Efficacy And Safety Of Eltrombopag Combining Rituximab With Eltrombopag In Adult ITP Patients
Actual Study Start Date : August 10, 2020
Estimated Primary Completion Date : February 10, 2022
Estimated Study Completion Date : August 10, 2022


Arm Intervention/treatment
Experimental: efficacy of eltrombopag combining rituximab

After enrollment,all subjects receive eltrombopag treatment,the initial dose of eltrombopag administration was an oral 75 mg once daily.Complete blood count including platelet count was done once a week.The dose of eltrombopag was adjusted according to the subject platelet count during the period from week 1 to week 24. If the platelet count >250×10^9/L, the eltrombopag will stop until the platelet count <30×10^9/L.

All subjects receive single dose infusion of rituximab 375 mg/m(2) within 14 days after enrollment.

Efficacy and safety will be evaluated at Week 4, Week 8, and Week 12.

Drug: eltrombopag combining rituximab

After enrollment,all subjects receive eltrombopag treatment,the initial dose of eltrombopag administration was an oral 75 mg once daily.Complete blood count including platelet count was done once a week.The dose of eltrombopag was adjusted according to the subject platelet count during the period from week 1 to week 24. If the platelet count >250×10^9/L, the eltrombopag will stop until the platelet count <30×10^9/L.

All subjects receive single dose infusion of rituximab 375 mg/m(2) within 14 days after enrollment.

Efficacy and safety will be evaluated at Week 4, Week 8, and Week 12.

Other Name: TPO-R agonist & anti-CD20 antibody

Active Comparator: efficacy of eltrombopag

After enrollment,all subjects receive eltrombopag treatment,the initial dose of eltrombopag administration was an oral 75 mg once daily.Complete blood count including platelet count was done once a week.The dose of eltrombopag was adjusted according to the subject platelet count during the period from week 1 to week 24. If the platelet count >250×10^9/L, the eltrombopag will stop until the platelet count <30×10^9/L.

Efficacy and safety will be evaluated at Week 4, Week 8, and Week 12.

Drug: eltrombopag

After enrollment,all subjects receive eltrombopag treatment,the initial dose of eltrombopag administration was an oral 75 mg once daily.Complete blood count including platelet count was done once a week.The dose of eltrombopag was adjusted according to the subject platelet count during the period from week 1 to week 24. If the platelet count >250×10^9/L, the eltrombopag will stop until the platelet count <30×10^9/L.

Efficacy and safety will be evaluated at Week 4, Week 8, and Week 12.

Other Name: TPO-R agonist




Primary Outcome Measures :
  1. Treatment response [ Time Frame: From the start of study treatment (Day 1) up to the end of week 12. ]
    Number of participants achieving a platelet count >=30×10^9/L and at least doubling of the baseline count at Week 4, Week 8, and Week 12 .


Secondary Outcome Measures :
  1. Drug efficacy [ Time Frame: From the start of study treatment (Day 1) up to the end of week 4, week 8 and week 12. ]
    Number of participants achieving a platelet count >=30×10^9/L at week 4, week 8, and week 12 in ITP patients with positive autoantibody

  2. Long-term treatment response [ Time Frame: From the start of study treatment (Day 1) up to the end of week 16, week 20 and week 24 ]
    Number of participants achieving a platelet count >=30×10^9/L at week 16, week 20, and week 24.

  3. Time to Response [ Time Frame: From the start of study treatment (Day 1) up to the end of week 24 ]
    Time to response is defined as time from the start of treatment to the first time of achieving a platelet count >=30×10^9/L and at least doubling of the baseline count during the whole 24 weeks.

  4. Duration of response [ Time Frame: From the start of study treatment (Day 1) up to the end of week 24. ]
    Total duration of time a participant had a platelet count >=30×10^9/L

  5. Evaluation of effectiveness [ Time Frame: From the start of study treatment (Day 1) up to the end of week 24. ]
    Number of participants that reduced or discontinued baseline concomitant ITP medications during the whole 24 weeks.

  6. Number of participants with clinically significant bleeding as assessed using the world health organization (WHO) bleeding scale. [ Time Frame: From the start of study treatment (Day 1) up to the end of week 24. ]
    The WHO Bleeding Scale is a measure of bleeding severity with the following grades: grade 0 = no bleeding, grade 1= petechiae, grade 2= mild blood loss, grade 3 = gross blood loss, and grade 4 = debilitating blood loss.

  7. Immune Thrombocytopenia Patient Assessment Questionnaire (ITP-PAQ) [ Time Frame: From the start of study treatment (Day 1) up to the end of week 24. ]
    In all participants ,use ITP-PAQ to assess the HRQoL before and after treatment.

  8. Functional Assessment of Chronic Illness Therapy fatigue subscale (FACIT-F) [ Time Frame: From the start of study treatment (Day 1) up to the end of week 24. ]
    In all participants ,use FACIT-F to assess the HRQoL before and after treatment.

  9. Number of Participants with side effects of the drugs [ Time Frame: From the start of study treatment (Day 1) up to the end of week 24. ]
    Side effects of the drugs included fever, headache, serum disease,hypotension, rashes, infection liver injury, hypokalaemia, etc.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Signed written informed consent
  2. Age from 18 to 60 years old
  3. Diagnosed with ITP and have a platelet count of <30 ×10^9/L on Day 1 (or within 48 hours prior to dosing on Day 1).
  4. Patients who have no response or relapsed after splenectomy(at least more than 6 months). Or patients who have not been splenectomised and have either not responded to one or more prior therapies, or who have relapsed prior therapy.
  5. Subjects treated with previous therapy(including but not limited to corticosteroid, azathioprine, danazol, cyclosporin A, mycophenolate mofetil) must have been completed prior to randomization, or must not be increasing a dose after enrollment.
  6. No pre-existing cardiac disease within the last 3 months. No arrhythmia known to increase the risk of thrombolic events (e.g. atrial fibrillation), or patients with a Corrected QT interval (QTc) >450msec or QTc >480 for patients with a Bundle Branch Block.
  7. No pre-existing infection within the last 1 months(including but not limited to pulmonary infection)
  8. Laboratory tests for coagulation function showed that prothrombin time (PT/INR) and activated partial thromboplastin time (APTT) no exceed normal by more than 20%. No history of clotting disorder, other than ITP.
  9. White blood cell count, neutrophil absolute value, hemoglobin, within the reference range, with the following exceptions:

    • Hemoglobin: females and males 10.0 g/dl are eligible for inclusion,
    • Absolute neutrophil count (ANC) ≥1500/µL (1.5×109/L) is required for inclusion
  10. The following blood chemistry test result no exceed normal by more than 20%:alanine aminotransferase, aspartate aminotransferase, total bilirubin, creatinine,serum albumin must not be below the lower limit of normal (LLN) by more than 10%.
  11. Subject is non-childbearing potential of childbearing potential and use acceptable methods of contraception throughout the study.
  12. Subjects fully understand and are able to comply with the requirements of the research protocol and are willing to complete the study as planned.

Exclusion Criteria:

  1. Patients with any prior history of arterial or venous thrombosis, and with following risk factors: cancer, Factor V Leiden, ATIII deficiency, antiphospholipid syndrome.
  2. Pregnant or lactating women;
  3. Subjects is currently receiving treatment with another study medication.
  4. Any laboratory or clinical evidence for HIV infection.
  5. Any clinical history for hepatitis C infection; chronic hepatitis B infection; or any evidence for active hepatitis at the time of subject screening. Laboratory test shows positive serology for Hepatitis C or Hepatitis B (HB). In addition, if negative for HBsAg but HBcAb positive (regardless of HBsAb status), a HB DNA test will be performed and if positive the subject will be excluded.
  6. History of platelet aggregation that prevents reliable measurement of platelet counts.
  7. Any clinically relevant abnormality, other than ITP,which in the opinion of the investigator makes the subject unsuitable for participation in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04518475


Contacts
Layout table for location contacts
Contact: Lei Zhang +86 13502118379 zhanglei1@ihcams.ac.cn

Locations
Layout table for location information
China
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Recruiting
Tianjin, China
Contact: Xiaofan Liu    +86 13752006059    liuxiaofan@ihcams.ac.cn   
Principal Investigator: Lei Zhang         
Sponsors and Collaborators
Institute of Hematology & Blood Diseases Hospital
The Second Affiliated Hospital of Kunming Medical University
Henan Cancer Hospital
Tianjin Medical University Second Hospital
The First Affiliated Hospital of Xiamen University
Nantong University
Investigators
Layout table for investigator information
Principal Investigator: Lei Zhang, M.D., Ph.D Institute of Hematology and Blood Diseases Hospital
Layout table for additonal information
Responsible Party: Zhang Lei, Professor/Vice director of Thrombosis &Hemostasis Center, Institute of Hematology & Blood Diseases Hospital
ClinicalTrials.gov Identifier: NCT04518475    
Other Study ID Numbers: IHBDH-IIT2020014
First Posted: August 19, 2020    Key Record Dates
Last Update Posted: August 19, 2020
Last Verified: August 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Zhang Lei, Institute of Hematology & Blood Diseases Hospital:
immune thrombocytopenia
autoantibody
eltrombopag
rituximab
Additional relevant MeSH terms:
Layout table for MeSH terms
Thrombocytopenia
Immune System Diseases
Purpura, Thrombocytopenic, Idiopathic
Blood Platelet Disorders
Hematologic Diseases
Purpura, Thrombocytopenic
Purpura
Blood Coagulation Disorders
Thrombotic Microangiopathies
Hemorrhagic Disorders
Autoimmune Diseases
Hemorrhage
Pathologic Processes
Skin Manifestations
Rituximab
Antineoplastic Agents, Immunological
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents